CCM
NBIX icon

Coldstream Capital Management’s Neurocrine Biosciences NBIX Stock Holding History

Coldstream Capital Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$465K Sell
3,527
-705
-17% -$93.5K 0.01% 757
2025
Q4 		$600K Buy
4,232
+142
+3% +$20.6K 0.01% 641
2025
Q3 		$574K Buy
4,090
+315
+8% +$42.7K 0.01% 681
2025
Q2 		$474K Buy
3,775
+125
+3% +$14.3K 0.01% 682
2025
Q1 		$404K Sell
3,650
-429
-11% -$54.3K 0.01% 706
2024
Q4 		$557K Buy
4,079
+162
+4% +$20K 0.01% 560
2024
Q3 		$452K Buy
3,917
+516
+15% +$70.7K 0.01% 643
2024
Q2 		$468K Buy
3,401
+47
+1% +$6.45K 0.01% 576
2024
Q1 		$463K Buy
3,354
+146
+5% +$19.9K 0.01% 585
2023
Q4 		$423K Buy
3,208
+868
+37% +$99.9K 0.01% 573
2023
Q3 		$263K Buy
+2,340
New +$246K 0.01% 643
2023
Q2 		– Sell
-2,796
Closed -$283K – 855
2023
Q1 		$283K Sell
2,796
-577
-17% -$60K 0.01% 644
2022
Q4 		$403K Buy
+3,373
New +$395K 0.01% 496
2022
Q2 		$305K Buy
3,123
+891
+40% +$82.2K 0.01% 558
2022
Q1 		$209K Buy
+2,232
New +$189K 0.01% 736

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Coldstream Capital Management's NBIX Position: Q1 2026 in Review

Coldstream Capital Management reduced its Neurocrine Biosciences (NBIX) stake by 17% in Q1 2026, selling an estimated $93.5K and leaving 3,527 shares worth $465K. The position accounts for 0.01% of the portfolio, ranked #757.

Coldstream Capital Management first reported a position in NBIX in Q1 2022 and has held it in 15 quarters since. The position peaked at $600K in Q4 2025. 696 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • Coldstream Capital Management held 3,527 shares of Neurocrine Biosciences worth $465K as of Q1 2026.
  • Coldstream Capital Management sold 705 Neurocrine Biosciences shares in Q1 2026, an estimated $93.5K.
  • Neurocrine Biosciences made up 0.01% of Coldstream Capital Management's portfolio in Q1 2026, its #757 holding.
  • Coldstream Capital Management first reported a position in Neurocrine Biosciences in Q1 2022 and has held it in 15 quarters since.
  • Coldstream Capital Management's Neurocrine Biosciences position peaked at $600K in Q4 2025.
  • 696 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Coldstream Capital Management's 13F filing for Q1 2026, filed 8 May 2026.